Compare · AZN vs ENVB
AZN vs ENVB
Side-by-side comparison of AstraZeneca PLC (AZN) and Enveric Biosciences Inc. (ENVB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ENVB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $563.07B, about 87388.3x ENVB ($6.4M).
- Over the past year, AZN is down 3.5% and ENVB is down 88.8% - AZN leads by 85.3 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 12 for ENVB).
- AZN has more recent analyst coverage (25 ratings vs 3 for ENVB).
- Company
- AstraZeneca PLC
- Enveric Biosciences Inc.
- Price
- $181.67-2.33%
- $1.75-1.13%
- Market cap
- $563.07B
- $6.4M
- 1M return
- -0.57%
- -43.91%
- 1Y return
- -3.51%
- -88.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 21
- 12
- Recent ratings
- 25
- 3
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Enveric Biosciences Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest ENVB
- Chief Financial Officer Coveney Kevin Michael was granted 133,333 shares, increasing direct ownership by 281% to 180,746 units (SEC Form 4)
- Chief Executive Officer Tucker Joseph Edward was granted 201,124 shares, increasing direct ownership by 286% to 271,479 units (SEC Form 4)
- Director Pasqualone Frank was granted 18,518 shares, increasing direct ownership by 234% to 26,423 units (SEC Form 4)
- Director Webb Michael D was granted 18,518 shares, increasing direct ownership by 234% to 26,416 units (SEC Form 4)
- Director Schabacker Marcus was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)
- Director Kegler George A. was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)
- Director Dewitt Sheila was granted 18,518 shares, increasing direct ownership by 238% to 26,306 units (SEC Form 4)
- Chief Innovation Officer Facchini Peter J. was granted 25,000 shares, increasing direct ownership by 907% to 27,755 units (SEC Form 4)
- Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
- SEC Form S-8 filed by Enveric Biosciences Inc.